alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 51–75 of 123 studies in Frontiers in neurology (page 3 of 5) · 31,380 in the whole library · How the 0–100 score works

Download bibliography of these 123 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,851 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Deep Learning-Based Screening Test for Cognitive Impairment Using Basic Blood Test Data for Health Examination

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Frontiers in neurology 2020-12-14

There were significant positive correlations between the predicted MMSE scores and ground truth scores in the Patient and Healthy groups (r = 0.66, p < 0.001). 5 key findings →

Participants: 202 Evidence: low

Full summary, score breakdown and related studies → Original source

The association between cerebrospinal ferritin and soluble triggering receptor expressed on myeloid cells 2 along Alzheimer's continuum

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Frontiers in neurology 2022-11-03

Brain iron accumulation, which is indicated in the cerebrospinal fluid (CSF) ferritin, is associated with the development of Alzheimer's Disease (AD). 4 key findings →

Participants: 46 Evidence: low

Full summary, score breakdown and related studies → Original source

Altered Cerebellar Resting-State Functional Connectivity in Early-Stage Parkinson's Disease Patients With Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Frontiers in neurology 2021-08-25

Compared to healthy control subjects with no cognitive deficits, altered cerebellar FC were observed in early PD participants with both motor and cognitive deficits, but not in PD patients with normal cognition, nor elderly subjects showing signs of a cognitive impairment. 4 key findings →

Participants: 64 Evidence: low

Full summary, score breakdown and related studies → Original source

Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Frontiers in neurology 2025-07-09

The performance characteristics of the Simoa p-Tau 217 assay align with current accuracy recommendations for blood-based biomarker test performance for diagnostic use, making the test suitable for clinical use under the Clinical Laboratory Improvement Act (CLIA) as a diagnostic plasma test to aid in Alzheimer's diagnosis. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Sarcopenia and Muscle Functions at Various Stages of Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Frontiers in neurology 2018-08-28

Although sarcopenia is closely linked to dementia, particularly Alzheimer disease (AD), there are few studies examining the prevalence and associated factors of sarcopenia in subjects with AD. 4 key findings →

Participants: 82 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Schizophrenia and dementia across the lifespan: epidemiological links, cognitive trajectories, and the pathophysiological interplay

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Frontiers in Neurology 2026-04-07

Epidemiological studies consistently indicate a two- to threefold increased risk of dementia among individuals with schizophrenia, although estimates vary due to diagnostic and ascertainment biases. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Frontiers in neurology 2015-11-27

The combination of decreased amyloid β42 (Aβ42) and increased total tau proteins (T-Tau) and phosphorylated tau (P-Tau) in cerebrospinal fluid (CSF) has recently been considered as a biological diagnostic criterion of Alzheimer's disease (AD). 2 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source

The clinical value of multimodal neuroimaging in monoclonal antibody therapy for Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Frontiers in neurology 2026-05-08

Multimodal neuroimaging plays an indispensable role in the diagnosis, monitoring, and therapeutic evaluation of monoclonal antibody (mAb) therapies for Alzheimer's disease (AD). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Machine Learning-Based Framework for Differential Diagnosis Between Vascular Dementia and Alzheimer's Disease Using Structural MRI Features

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Frontiers in neurology 2019-10-25

The experimental results demonstrate that the SVM with RBF achieved an encouraging performance with sensitivity (SEN), specificity (SPE), and accuracy (ACC) values of 82.65%, 87.17%, and 84.35%, respectively (AUC = 0.861, 95% CI = 0.820-0.902), for the differential diagnosis between VaD and AD. 2 key findings →

Participants: 93 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Gait characteristics and factors associated with fall risk in patients with dementia with Lewy bodies

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Frontiers in Neurology 2025-09-24

Gait abnormalities are associated with cognitive decline, and reduced gait speed and gait asymmetry are markers of cognitive decline and increased fall risk in patients with established DLB. 5 key findings →

Design: cross-sectional Participants: 63 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Polygenic risk for white matter hyperintensities is associated with early cerebrovascular events partly through hemodynamic measures in cognitively unimpaired middle-aged and older adults with low cardiovascular risk

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Frontiers in Neurology 2026-01-05

They are often found in middle-aged individuals and are associated with a greater risk of stroke and vascular dementia. 5 key findings →

Participants: 1,072 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Regional differences in the incidence of Alzheimer’s disease and related dementias in South Carolina

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in Neurology 2025-09-05

Regional differences in the incidence of ADRD suggest possible disparities in healthcare access, socioeconomic conditions and geographical factors. 2 key findings →

Participants: 18,955 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Artificial intelligence in neurodegenerative diseases research: a bibliometric analysis since 2000

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in Neurology 2025-07-16

This bibliometric review examines the evolving landscape of artificial intelligence (AI) in neurodegenerative diseases research from 2000 to March 16, 2025, utilizing data from 1,402 publications (1,159 articles, 243 reviews) indexed in the Web of Science Core Collection. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Research progress in predicting the conversion from mild cognitive impairment to Alzheimer’s disease via multimodal MRI and artificial intelligence

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in Neurology 2025-06-02

Predicting the transition from mild cognitive impairment (MCI) to Alzheimer's disease (AD) has important clinical significance for dementia prevention and improving patient prognosis. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A novel tablet-based software for the acquisition and analysis of gaze and eye movement parameters: a preliminary validation study in Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in neurology 2023-06-15

The idea that eye movements can reflect certain aspects of brain function and inform on the presence of neurodegeneration is not a new one. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events